Multiple Myeloma

Patients with newly diagnosed, transplant-eligible multiple myeloma continue to experience robust and durable responses to treatment with daratumumab, lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant followed by daratumumab plus lenalidomide maintenance.

Ciltacabtagene autoleucel as a single infusion led to early, durable responses, and demonstrated positive minimal residual disease negativity for patients with multiple myeloma who had early clinical relapse.

In an assessment of 2 patient cases of relapsed or refractory multiple myeloma with translocations in t(11;14), selinexor plus venetoclax was safe and efficacious.

The treatment combination of selinexor plus pomalidomide and dexamethasone at the recommended phase 2 dose produced more durable and deep responses than the lesser selinexor dose for relapsed or refractory multiple myeloma.

Data for ciltacabtagene autoleucel from CARTITUDE-1 show that use in the setting of heavily pretreated multiple myeloma bests standard-of-care treatments.

Thomas G. Martin, MD, spoke about the updated results of the CARTITUDE-1 study examining ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.

Induction and consolidation with daratumumab, ixazomib, lenalidomide, and dexamethasone was able to induce minimal residual disease in a subset of patients with transplant-eligible newly diagnosed multiple myeloma and standard-risk disease.

Among patients with newly diagnosed multiple myeloma, 80% of a study cohort reached MRD negativity following treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Weekly selinexor combined with bortezomib and dexamethasone appears to be a promising option in patients with high-risk multiple myeloma.

A population of patients with relapsed/refractory multiple myeloma appeared to benefit from treatment with selinexor plus daratumumab, bortezomib, and dexamethasone

Adding isatuximab to lenalidomide, bortezomib, and dexamethasone demonstrated a superior minimal residual disease rate in patients with transplant-eligible newly diagnosed multiple myeloma.

The combination of daratumumab with bortezomib, cyclophosphamide, and dexamethasone continued to improve hematologic and organ responses after 18 months of follow-up.

Findings from the phase 1b TRIMM-2 study indicated that patients with relapsed/refractory multiple myeloma experienced manageable toxicities and promising responses to treatment with talquetamab and daratumumab.

Research presented at the 63rd ASH Annual Meeting and Exposition found significantly higher MRD-negativity and sustained MRD-negativity rates among patients with transplant-eligible newly diagnosed multiple myeloma receiving D-VTd over VTd alone.

Patients with newly diagnosed multiple myeloma who are non-transplant eligible and intermediate-fit and who received a less toxic regimen of ixazomib, daratumumab, and low-dose dexamethasone demonstrated higher rates of objective response.

A phase 2 trial shows promise of the daratumumab/ixazomib combination in frail and elderly patients with multiple myeloma who are treated in the relapsed setting when given without dexamethasone.

Patients receiving daratumumab, lenalidomide, and dexamethasone in the first line saw better overall survival than those who waited and received second-line daratumumab-based regimens for transplant-ineligible newly diagnosed multiple myeloma.

Luciano Costa, MD, PhD, spoke about which abstracts he wants to see most at ASH 2021.

Thomas G. Martin, MD, spoke about the previously reported results of the CARTITUDE-1 study in patients with relapsed or refractory myeloma ahead of the 2021 ASH Annual Meeting.

Thomas G. Martin, MD, spoke about the abstracts regarding B-cell maturation antigen–targeted treatments he’s excited to see presented at ASH 2021.

Nina Shah, MD, touched on important abstracts being presented at the 2021 American Society of Hematology Annual Meeting.

Thomas G. Martin, MD, spoke about different abstracts to be presented at ASH 2021.

Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.

Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.

Panobinostat, which received accelerated approval by the FDA in February 2015 for patients with previously treated multiple myeloma, has had its indication withdrawn in the United States.